Indian Immunologicals Restricted (IIL), the makers of anti rabies vaccine, Abhayrab this day clarified that it had “proactively” identified a packaging anomaly in a single batch and that the counterfeit batch is “now no longer” on hand on the shelves because it kind to allay the fears after the Australian health authorities issued an urgent public health alert following a detection it counterfeit batches of rabies vaccine circulating in India.
An alert used to be released by the Australian Technical Advisory Group on Immunisation (ATAGI) and declare health departments, which warned that travellers who got this vaccine in India since November 1, 2023, will be fully unprotected in opposition to the virus.
“Importantly this used to be an isolated incident,” it acknowledged in an announcement.
It acknowledged that the it had identified the packaging anomaly in January 2025 (batch #KA 24014). The firm acknowledged that it had notified the Indian regulators and regulation enforcement agencies, lodged a formal grievance and labored carefully with authorities to be sure swift fade, it acknowledged.
The firm strongly refuted the over-cautionary and misplaced reference to 2023 made in a as a lot as date Australian health advisory, stressing that the advisory doesn’t mediate the modern field.
Abhayrab has been manufactured by IIL since 2000, with extra than 210 million doses equipped in some unspecified time in the future of India and 40 worldwide locations, and continues to take care of a 40% market half in India.
Reassuring healthcare professionals and the overall public, IIL emphasized that every batch of vaccine manufactured in India is tested and released by the Central Capsules Laboratory (Govt of India) prior to being made on hand on the market or administration. “Offers made by authorities institutions and licensed distributors live safe and of long-established quality,” it extra acknowledged.
Sunil Tiwari, Vice President & Head of Quality Management at IIL, acknowledged that IIL targets to reassure stakeholders that the firm’s pharmacovigilance and quality programs are sturdy, and that the overall public can continue to space confidence in vaccines equipped straight by IIL and its licensed channels.
